Literature DB >> 26451012

Update on dalbavancin activity tested against Gram-positive clinical isolates responsible for documented skin and skin-structure infections in US and European hospitals (2011-13).

Rodrigo E Mendes1, Mariana Castanheira2, David J Farrell2, Robert K Flamm2, Helio S Sader2, Ronald N Jones2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26451012     DOI： 10.1093/jac/dkv303

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  6 in total

Review 1.  Single-Dose Dalbavancin: A Review in Acute Bacterial Skin and Skin Structure Infections.

Authors:  Karly P Garnock-Jones
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

2.  New Evidence and Insights on Dalbavancin and Wound Healing in a Mouse Model of Skin Infection.

Authors:  Oriana Simonetti; Guendalina Lucarini; Gianluca Morroni; Fiorenza Orlando; Raffaella Lazzarini; Antonio Zizzi; Lucia Brescini; Mauro Provinciali; Andrea Giacometti; Annamaria Offidani; Oscar Cirioni
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

3.  Antimicrobial Activity of Dalbavancin against Staphylococcus aureus with Decreased Susceptibility to Glycopeptides, Daptomycin, and/or Linezolid from U.S. Medical Centers.

Authors:  Helio S Sader; Rodrigo E Mendes; Leonard R Duncan; Michael A Pfaller; Robert K Flamm
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 4.  Dalbavancin for the treatment of paediatric infectious diseases.

Authors:  S Esposito; S Bianchini
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-08-25       Impact factor: 3.267

5.  Real-world experience with dalbavancin therapy in gram-positive skin and soft tissue infection, bone and joint infection.

Authors:  Selma Tobudic; Christina Forstner; Heinz Burgmann; Heimo Lagler; Christoph Steininger; Ludwig Traby; Mathias G Vossen; Stefan Winkler; Florian Thalhammer
Journal:  Infection       Date:  2019-09-13       Impact factor: 3.553

6.  Comparative In Vitro Activities of New Antibiotics for the Treatment of Skin Infections.

Authors:  Dee Shortridge; Robert K Flamm
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.